Foghorn Therapeutics financials
$3.520.00%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M | $430.0K |
| Gross profit | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M | $430.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$86.4M | -$102.7M | -$107.9M | -$117.1M | -$100.7M | -$68.5M |
| Net income | -$74.3M | -$86.6M | -$98.4M | -$108.9M | -$101.3M | -$68.8M |
| Net margin | −240.3% | −383.2% | −288.2% | −566.3% | −7681.6% | −16000.0% |
| Diluted EPS | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 | $-6.23 |
| EBITDA | -$77.1M | -$97.2M | -$104.5M | -$113.8M | -$97.5M | -$67.2M |
| Operating cash flow | -$86.1M | -$100.4M | -$118.1M | $193.6M | -$50.3M | -$31.3M |
| Free cash flow | -$86.1M | -$101.3M | -$119.3M | $192.4M | -$53.6M | -$47.5M |
| Diluted shares | 63.0M | 54.9M | 42.0M | 41.6M | 37.2M | 11.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $80.9M | $55.5M | $80.3M | $52.2M | $101.1M | $92.8M |
| Short-term investments | $78.0M | $188.3M | $153.7M | $293.6M | $53.2M | $93.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $19.7M |
| Total assets | $198.1M | $284.0M | $285.9M | $404.9M | $519.8M | $255.6M |
| Total liabilities | $306.6M | $329.5M | $363.1M | $404.8M | $422.9M | $109.4M |
| Shareholders' equity | -$108.5M | -$45.5M | -$77.2M | $112.0K | $96.9M | $146.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology